Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Last Wednesday, Apotex Inc. learned there may be serious problems with one lot of its generic birth control pill Alysena after a customer found her pill package contained an extra week of sugar pills.

Handout/The Canadian Press

Anger over a bungled birth control pill recall is continuing to grow, despite assurances the federal health minister is launching an investigation into the matter.

The Globe and Mail reported Thursday that Health Minister Leona Aglukkaq has ordered Health Canada to investigate why it took so long to inform women taking Alysena their birth control pills were under recall.

Last Wednesday, Apotex Inc. learned there may be serious problems with one lot of its generic birth control pill Alysena after a customer found her pill package contained an extra week of sugar pills. One week of sugar pills is typically included in a 28-day pack to remind women to take the pills each day. An extra week of sugar pills puts women at risk of accidental pregnancy.

Story continues below advertisement

Apotex informed Health Canada of the problem last Thursday. However, Health Canada and Apotex failed to inform the general public of the problem until last Monday, nearly a week after the problem was first identified. A Health Canada spokeswoman explained that an urgent recall was not issued immediately because the problem with the pill was not considered life-or-death. Instead, the department and Apotex issued a "Class II" recall, reserved for products that may cause temporary health issues, or where the probability of a serious health impact is low.

In other words, risk of accidental pregnancy was not deemed serious enough to trigger an urgent product recall.

The department upgraded the recall on Monday to a Class I recall after realizing some women who shouldn't become pregnant for medical reasons could be affected.

Health Canada spokeswoman Blossom Leung said in an e-mail the recall assessment takes health impacts into account, not "lifestyle impacts" such as unplanned pregnancy, which is why the urgent product recall was only issued Monday.

Jennifer Blake, CEO of the Society of Obstetricians and Gynaecologists of Canada, said the response to the recall is unacceptable and that the organization was "dumbfounded" to learn women weren't informed of the problem with Alysena for days.

"The delay in issuing a Class I recall is inexplicable," Blake said in an e-mail Friday. "Women had protective actions they could have taken immediately, had they known."

In addition to the timing, the recall also raises important questions about whether Health Canada's quality-control processes are adequate, particularly when it comes to drugs manufactured overseas.

Story continues below advertisement

Alysena is produced in Spain by Laboratorios Leon Farma and distributed in Canada by Apotex. There have been growing concerns over the quality and safety of drugs produced overseas and many health advocates question whether Health Canada is doing enough to ensure overseas plants are following good manufacturing practices.

Blake said the Alysena recall represents "an unacceptable lapse in quality control" and that Canadians need answers as to whether the drug supply is safe.

Brian Stowe, an independent pharmacist and owner of the Prescription Shop on the campus of Carleton University in Ottawa, said the recall is the latest in a string of problems involving generic birth control pills. The generic brands of birth control pills are often facing shortages, meaning patients are forced to constantly switch brands, which can lead to unwanted side effects, such as bleeding. Stowe said these problems are exacerbated by the drive to lower the cost of generic drug prices in Canada, because it encourages drug firms to sell their product in more lucrative markets.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies